Abattis Bioceuticals (ATTBF) Stock Price, News & Analysis

Company Overview

Abattis Bioceuticals Corp. (OTCMKTS: ATTBF) is a Canadian company specializing in the extraction, purification and formulation of cannabinoids for both medicinal and recreational markets. Headquartered in British Columbia, the company operates a cGMP-compliant facility that applies proprietary extraction techniques to produce high-purity distillates, isolates and winterized oils from both hemp and cannabis biomass.

The company’s core services include contract extraction and white-label manufacturing for licensed producers and ancillary businesses. Abattis offers a range of finished-product formats, including vape cartridges, tinctures, edibles and water-soluble cannabinoid powders, catering to pharmaceutical, nutraceutical and consumer packaged goods applications. Its in-house R&D team develops novel delivery systems designed to optimize bioavailability and consistency.

Abattis serves clients across Canada and maintains strategic partnerships to explore international markets in Europe and Latin America. The firm’s extraction facility near Vancouver supports pilot-scale and commercial-scale runs, while a dedicated quality assurance laboratory conducts testing for potency, terpene profiles and residual solvents. The company also holds Health Canada licenses for both cultivation and processing.

Founded in 2014, Abattis Bioceuticals has grown through a series of acquisitions and technology alliances, including the 2018 purchase of LightRail Health Sciences’ extraction assets. The company is led by Chief Executive Officer Nelson Bocella, who brings experience in pharmaceutical manufacturing and supply-chain management, and works alongside a management team with backgrounds in chemical engineering, regulatory compliance and product commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 7,500 shs
• Average Volume: 11,650 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATTBF Stock Analysis - Frequently Asked Questions

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ATTBF
• CIK: N/A
• Web: www.abattis.com
• Phone: 808-650-3007
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A